Cargando…
Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma
In most myeloma patients, even after several rounds of intensive therapy, drug resistant tumor cells survive and proliferate aggressively leading to relapse. In the present study, gene expression profiling of tumor cells isolated from myeloma patients after sequential rounds of chemotherapy, reveale...
Autores principales: | Ramani, Vishnu C., Zhan, Fenghuang, He, Jianbo, Barbieri, Paola, Noseda, Alessandro, Tricot, Guido, Sanderson, Ralph D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811483/ https://www.ncbi.nlm.nih.gov/pubmed/26624982 |
Ejemplares similares
-
Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
por: Gu, Chunyan, et al.
Publicado: (2018) -
Correction to: Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
por: Gu, Chunyan, et al.
Publicado: (2019) -
NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma
por: Hao, M, et al.
Publicado: (2017) -
Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome
por: Gu, Chunyan, et al.
Publicado: (2018) -
Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
por: Franqui-Machin, Reinaldo, et al.
Publicado: (2015)